Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications

International Journal of Impotence Research

Volumn 19, Issue 4, 2007, Pages 386-392

  Seftel, A ^a   Rosen, R ^a   Kuritzky, L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benign prostatic hyperplasia; Drug therapy; Ejaculatory dysfunction; Impotence; Lower urinary tract symptoms; Physician specialty; Physician survey; Prevalence; Sexual dysfunction

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARCINOMA; CLINICAL OBSERVATION; CONTROLLED STUDY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HEALTH SURVEY; HUMAN; INCIDENCE; INTERNAL MEDICINE; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; PHYSICIAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; UROLOGY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANDROGEN ANTAGONISTS; ATTITUDE OF HEALTH PERSONNEL; DATA COLLECTION; EJACULATION; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PHYSICIANS; PHYSICIANS, FAMILY; PROSTATIC HYPERPLASIA; QUESTIONNAIRES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE 5-ALPHA-REDUCTASE; UROLOGIC DISEASES; UROLOGY;

EID: 34347400460     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901540     Document Type: Article

References (39)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
2. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997; 31: 272-280.
3. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-436.
4. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002; 59: 245-250.
5. Blanker MH, Bosch JL, Groeneveld FP et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001; 57: 763-768.
6. Blanker MH, Bohnen AM, Groeneveld FP et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49: 436-442.
7. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-649.
8. Frankel SJ, Donovan JL, Peters TI et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677-685.
9. Tubaro A, Polito M, Giambroni L, Famulari C, Gange E, Ostardo E. Sexual function in patients with LUTS suggestive of BPH. Eur Urol 2001; 40(Suppl 1): 19-22.
10. Vallancien G, Emberton M, Harving N, van Moorselaar RJ. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257-2261.
11. Enzlin P, Mak R, Kittel F, Demyttenaere K. Sexual functioning in a population-based study of men aged 40-69 years: the good news. Int J Impot Res 2004; 16: 512-520.
12. McCabe MP. Intimacy and quality of life among sexually dysfunctional men and women. J Sex Marital Ther 1997; 23: 276-290.
13. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-311.
14. Rosen RC, Seidman SN, Menza MA et al. Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004; 16: 334-340.
15. Dahn JR, Penedo FJ, Gonzalez JS et al. Sexual functioning and quality of life after prostate cancer treatment: considering sexual desire. Urology 2004; 63: 273-277.
16. Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how? Eur Urol 1999; 36(Suppl 3): 7-13.
17. Lukacs B. Management of symptomatic BPH in France: who is treated and how? Eur Urol 1999; 36(Suppl 3): 14-20.
18. AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. AUA Practice Guidelines Committee. J Urol 2003; 170: 530-547.
19. Carbone Jr DJ, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 2003; 15: 299-306.
20. FLOMAX (tamsulosin hydrochloride) [prescribing information] Boehringer Ingelheim Pharmaceuticals, Inc.: Ridgefield, CT, 2005.
21. Nickel JC, Fradet Y, Boake RC et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996; 155: 1251-1259.
22. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-441.
23. Baldwin K, Ginsberg P, Harkaway RC. Under-reporting of erectile dysfunction among men with unrelated urologic conditions. Int J Impot Res 2003; 15: 87-89.
24. Kitai E, Vinker S, Kijner F, Lustman A. Erectile dysfunction - the effect of sending a questionnaire to patients on consultations with their family doctor. Fam Pract 2002; 19: 247-250.
25. Hakim J, Subit M, Kandzari S, Zaslau S. Quality control in the screening of erectile dysfunction results of a survey. Urology 2002; 60: 125-129.
26. Rutchik SD, Baudiere M, Wade M, Sullivan G, Rayford W, Goodman J. Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians. Urology 2001; 57: 146-150.
27. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002; 324: 1059-1061.
28. Fisher W, Rosen R, Eardley I et al. The multinational Men's Attitides to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns among men with erectile dysfunction. J Sex Med 2004; 1: 150-160.
29. Wei J, Nuckolls J, Miner M, Rosen R, Roehrborn C. Differences in medical management of LUTS/BPH between PCPs and urologists [abstract]. J Urol 2006; 175: 3.
30. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-126.
31. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335: 533-539.
32. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398.
33. Resnick M, Seftel A, Rosen R, Roehrborn C. Alfuzosin 10mg improves sexual function in BPH patients: preliminary results of a placebo controlled trial. Societe Internationale d'Urologie (SIU). Honolulu, Hawaii, 2004.
34. van Moorselaar RJ, Hartung R, Emberton M et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95: 603-608.
35. Elhilali M, Emberton M, Matzkin H et al. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. BJU Int 2006; 97: 513-519.
36. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200.
37. De Rose AF, Carmignani G, Corbu C et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002; 68: 95-98.
38. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836-839.
39. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341-2345.